Ghimire Hemendra, Sargur Madabushi Srideshikan, Vercellino Justin, Brooks Jamison, Zuro Darren, Lim Ji Eun, Vishwasrao Paresh, Abdelhamid Amr Mohamed Hamed, Strome Guy, Eichenbaum Gary, Al Malki Monzr, Guha Chandan, Hui Susanta K
Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA, United States.
Department of Radiation Oncology, Montefiore Medical Center, Bronx, NY, United States.
Front Oncol. 2024 Oct 10;14:1414488. doi: 10.3389/fonc.2024.1414488. eCollection 2024.
There is a need for therapies that can mitigate bone marrow dysfunction and organ toxicity that occur following myeloablative injury and reduced intensity conditioning regimens used in patients undergoing bone marrow transplantation (BMT). The pathogenesis of adverse effects from BMT conditioning has been linked to injury to the vascular endothelium, bone marrow (BM), and other organs.
To evaluate the impact of the thrombopoietin mimetic drug JNJ-26366821 (TPOm) on BM vascular recovery in mice undergoing myeloablative radiation conditioning followed by BMT.
TPOm (doses: 0 µg, 300 µg, 1000 µg per Kg body weight) was administered on Days 0 and 7 after BMT, in mice receiving a total body irradiation (TBI) conditioning regimen (5.5 Gy x 2) before congenic BMT. BM donner cell engraftment was analyzed using flow cytometry on Days 7, 14, and 30 post-BMT. The morphological and biophysical properties of the BM vasculature were evaluated by intravital multiphoton microscopy (MPM) and immunofluorescence confocal imaging. Herein, morphological properties involve microvascular density (MVD), vessel diameter, and vascular area, while biophysical properties include transfer rate (K) of contrast within the BM vascular niche, as well as the fractional volume ( ) of extracellular extravascular tissue (EES).
No significant difference in donor chimerism was observed at days 7, 14, and 30 post-BMT, between TPOm and PBS-treated mice. TPOm intervention improved BM vasculature regeneration in transplanted mice. The MVD, K and BM vasculature as well as vascular endothelial growth factor receptor-2 (VEGFR2) in the BM, showed a dose dependent improvement in mice treated with TPOm. On day 14 post-BMT, the group receiving 1000 µg/Kg TPOm showed significant shifts (p-value < 0.05) in MVD, K, and VEGFR2 expression from their corresponding control types (TPOm dose 0 µg) towards levels comparable to healthy controls.
TPOm intervention augments BM vascular structure and function, which may be important for hematopoietic recovery and bone marrow function in radiation conditioned hematopoietic stem cell transplant patients, in addition to enhancing platelet recovery.
对于接受骨髓移植(BMT)的患者,在进行清髓性损伤和降低强度预处理方案后,需要能够减轻骨髓功能障碍和器官毒性的治疗方法。BMT预处理不良反应的发病机制与血管内皮、骨髓(BM)和其他器官的损伤有关。
评估血小板生成素模拟药物JNJ-26366821(TPOm)对接受清髓性放射预处理后进行BMT的小鼠骨髓血管恢复的影响。
在同基因BMT前接受全身照射(TBI)预处理方案(5.5 Gy×2)的小鼠中,于BMT后第0天和第7天给予TPOm(剂量:每千克体重0 μg、300 μg、1000 μg)。在BMT后第7天、14天和30天,使用流式细胞术分析骨髓供体细胞植入情况。通过活体多光子显微镜(MPM)和免疫荧光共聚焦成像评估骨髓脉管系统的形态和生物物理特性。在此,形态学特性包括微血管密度(MVD)、血管直径和血管面积,而生物物理特性包括骨髓血管龛内造影剂的转运速率(K)以及细胞外血管外组织(EES)的分数体积( )。
在BMT后第7天、14天和30天,TPOm处理组和PBS处理组小鼠的供体嵌合率无显著差异。TPOm干预改善了移植小鼠的骨髓脉管系统再生。TPOm处理的小鼠中,MVD、K和骨髓脉管系统以及骨髓中的血管内皮生长因子受体-2(VEGFR2)呈现剂量依赖性改善。在BMT后第14天,接受1000 μg/Kg TPOm的组在MVD、K和VEGFR2表达方面与相应的对照类型(TPOm剂量0 μg)相比有显著变化(p值<0.05),接近健康对照水平。
TPOm干预增强了骨髓血管结构和功能,这除了能促进血小板恢复外,对于放射预处理的造血干细胞移植患者的造血恢复和骨髓功能可能也很重要。